No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ARTL Artelo Biosciences
- 1.3399
- -0.0001-0.01%
Close Apr 26 16:00 ET
- 1.3100
- -0.0299-2.23%
Post 17:02 ET
4.32MMarket Cap-426P/E (TTM)
1.3600High1.3109Low5.73KVolume1.3600Open1.3400Pre Close7.58KTurnover0.18%Turnover RatioLossP/E (Static)3.23MShares2.980052wk High0.37P/B4.28MFloat Cap1.150052wk Low--Dividend TTM3.20MShs Float75.0000Historical High--Div YieldTTM3.66%Amplitude1.1500Historical Low1.3230Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Artelo Biosciences Reports Publication Peer-Reviewed Article Titled "The Emerging Role of Fatty Acid Binding Protein 7 (FABP7) in Cancers,"
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people
Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.
Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Artelo Biosciences, Maintains $5 Price Target
Buy Rating on Artelo Biosciences: Strong Pipeline and Market Potential
Comments
$Artelo Biosciences(ARTL.US$
NEWS
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
NEWS
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Top after hours mover.
2.7 million float runner trading cash levels
$5 cash levels but trading 1.80 range.
Conference tomorrow at 12 pm EST.
$Artelo Biosciences(ARTL.US$
Called $SciSparc(SPRC.US$$SuperCom(SPCB.US$
$Novo Integrated Sciences(NVOS.US$
2.7 million float runner trading cash levels
$5 cash levels but trading 1.80 range.
Conference tomorrow at 12 pm EST.
$Artelo Biosciences(ARTL.US$
Called $SciSparc(SPRC.US$$SuperCom(SPCB.US$
$Novo Integrated Sciences(NVOS.US$
1
$Artelo Biosciences(ARTL.US$ Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12!
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg